The head of the Oxford Vaccine Group said Friday that clinic trials on its vaccine for the coronavirus are"progressing very well."
Oxford University has an exclusive deal with the company Oxford Sciences Innovation to commercialise all its research - and a SA fund manager is the largest shareholder in OSI.
لقد قمنا بتلخيص هذا الخبر حتى تتمكن من قراءته بسرعة. إذا كنت مهتمًا بالأخبار، يمكنك قراءة النص الكامل هنا. اقرأ أكثر: